First patient enrolled in study of BioLineRx's celiac treatment

BioLineRx (BLRX +1.8%) enrolls the first patient in a Phase 1/2 study of BL-7010 in celiac disease.

Results from the study — which is designed to "assess the safety of single and repeated ascending doses in well-controlled celiac patients" — are due in mid-2014. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs